OTCMKTS:VVUSQ

VIVUS Competitors

$0.12
0.00 (0.00 %)
(As of 12/17/2020)
Add
Compare
Today's Range
$0.12
Now: $0.12
$0.12
50-Day Range
$0.12
MA: $0.12
$0.12
52-Week Range
$0.07
Now: $0.12
$4.55
VolumeN/A
Average Volume937,537 shs
Market Capitalization$2.10 million
P/E RatioN/A
Dividend YieldN/A
Beta-3.25

Competitors

VIVUS (OTCMKTS:VVUSQ) Vs. ULUR, ACUR, PARNF, PVTTF, KAYS, and WCUI

Should you be buying VVUSQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to VIVUS, including ULURU (ULUR), Acura Pharmaceuticals (ACUR), Parnell Pharmaceuticals (PARNF), Pivotal Therapeutics (PVTTF), Kaya (KAYS), and Wellness Center USA (WCUI).

VIVUS (OTCMKTS:VVUSQ) and ULURU (OTCMKTS:ULUR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Valuation & Earnings

This table compares VIVUS and ULURU's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VIVUS$69.76 million0.03$-31,500,000.00($2.96)-0.04
ULURUN/AN/AN/AN/AN/A

ULURU has lower revenue, but higher earnings than VIVUS.

Profitability

This table compares VIVUS and ULURU's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VIVUS-39.28%N/A-12.18%
ULURUN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for VIVUS and ULURU, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VIVUS0000N/A
ULURU0000N/A

Insider & Institutional Ownership

7.3% of VIVUS shares are owned by institutional investors. 12.0% of VIVUS shares are owned by company insiders. Comparatively, 1.1% of ULURU shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

VIVUS has a beta of -3.25, meaning that its stock price is 425% less volatile than the S&P 500. Comparatively, ULURU has a beta of -2.9, meaning that its stock price is 390% less volatile than the S&P 500.

VIVUS (OTCMKTS:VVUSQ) and Acura Pharmaceuticals (OTCMKTS:ACUR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Valuation & Earnings

This table compares VIVUS and Acura Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VIVUS$69.76 million0.03$-31,500,000.00($2.96)-0.04
Acura Pharmaceuticals$2.66 million2.83N/AN/AN/A

Acura Pharmaceuticals has lower revenue, but higher earnings than VIVUS.

Profitability

This table compares VIVUS and Acura Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VIVUS-39.28%N/A-12.18%
Acura Pharmaceuticals-19.89%-1.36%-34.83%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for VIVUS and Acura Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VIVUS0000N/A
Acura Pharmaceuticals0000N/A

Insider & Institutional Ownership

7.3% of VIVUS shares are owned by institutional investors. 12.0% of VIVUS shares are owned by company insiders. Comparatively, 5.6% of Acura Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

VIVUS has a beta of -3.25, meaning that its stock price is 425% less volatile than the S&P 500. Comparatively, Acura Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Summary

VIVUS beats Acura Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

VIVUS (OTCMKTS:VVUSQ) and Parnell Pharmaceuticals (OTCMKTS:PARNF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Valuation & Earnings

This table compares VIVUS and Parnell Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VIVUS$69.76 million0.03$-31,500,000.00($2.96)-0.04
Parnell PharmaceuticalsN/AN/AN/AN/AN/A

Parnell Pharmaceuticals has lower revenue, but higher earnings than VIVUS.

Profitability

This table compares VIVUS and Parnell Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VIVUS-39.28%N/A-12.18%
Parnell PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for VIVUS and Parnell Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VIVUS0000N/A
Parnell Pharmaceuticals0000N/A

Insider & Institutional Ownership

7.3% of VIVUS shares are owned by institutional investors. 12.0% of VIVUS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

VIVUS has a beta of -3.25, meaning that its stock price is 425% less volatile than the S&P 500. Comparatively, Parnell Pharmaceuticals has a beta of 5, meaning that its stock price is 400% more volatile than the S&P 500.

VIVUS (OTCMKTS:VVUSQ) and Pivotal Therapeutics (OTCMKTS:PVTTF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Valuation & Earnings

This table compares VIVUS and Pivotal Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VIVUS$69.76 million0.03$-31,500,000.00($2.96)-0.04
Pivotal TherapeuticsN/AN/AN/AN/AN/A

Pivotal Therapeutics has lower revenue, but higher earnings than VIVUS.

Profitability

This table compares VIVUS and Pivotal Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VIVUS-39.28%N/A-12.18%
Pivotal TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for VIVUS and Pivotal Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VIVUS0000N/A
Pivotal Therapeutics0000N/A

Insider & Institutional Ownership

7.3% of VIVUS shares are owned by institutional investors. 12.0% of VIVUS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

VIVUS has a beta of -3.25, meaning that its stock price is 425% less volatile than the S&P 500. Comparatively, Pivotal Therapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.

VIVUS (OTCMKTS:VVUSQ) and Kaya (OTCMKTS:KAYS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Profitability

This table compares VIVUS and Kaya's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VIVUS-39.28%N/A-12.18%
Kaya-1,558.07%N/A-586.93%

Risk and Volatility

VIVUS has a beta of -3.25, meaning that its stock price is 425% less volatile than the S&P 500. Comparatively, Kaya has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for VIVUS and Kaya, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VIVUS0000N/A
Kaya01002.00

Valuation & Earnings

This table compares VIVUS and Kaya's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VIVUS$69.76 million0.03$-31,500,000.00($2.96)-0.04
Kaya$1.01 million6.28$7.80 millionN/AN/A

Kaya has lower revenue, but higher earnings than VIVUS.

Insider & Institutional Ownership

7.3% of VIVUS shares are owned by institutional investors. 12.0% of VIVUS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

VIVUS beats Kaya on 5 of the 8 factors compared between the two stocks.

Wellness Center USA (OTCMKTS:WCUI) and VIVUS (OTCMKTS:VVUSQ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Profitability

This table compares Wellness Center USA and VIVUS's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wellness Center USAN/AN/A-1,809.19%
VIVUS-39.28%N/A-12.18%

Volatility & Risk

Wellness Center USA has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, VIVUS has a beta of -3.25, indicating that its stock price is 425% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Wellness Center USA and VIVUS, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wellness Center USA0000N/A
VIVUS0000N/A

Valuation and Earnings

This table compares Wellness Center USA and VIVUS's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wellness Center USA$30,000.00193.98$-2,390,000.00N/AN/A
VIVUS$69.76 million0.03$-31,500,000.00($2.96)-0.04

Wellness Center USA has higher earnings, but lower revenue than VIVUS.

Insider & Institutional Ownership

0.1% of Wellness Center USA shares are owned by institutional investors. Comparatively, 7.3% of VIVUS shares are owned by institutional investors. 14.1% of Wellness Center USA shares are owned by insiders. Comparatively, 12.0% of VIVUS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Wellness Center USA beats VIVUS on 5 of the 8 factors compared between the two stocks.


VIVUS Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ULUR
ULURU
0.3$0.28flat$8.17 millionN/A0.00Decrease in Short Interest
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.34flat$7.52 million$2.66 million-11.33News Coverage
Parnell Pharmaceuticals logo
PARNF
Parnell Pharmaceuticals
0.5$0.36flat$7.20 millionN/A0.00News Coverage
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.08flat$7.15 millionN/A0.00
KAYS
Kaya
0.7$0.44flat$6.89 million$1.01 million0.00
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.05flat$5.82 million$30,000.000.00Gap Down
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.24flat$5.68 million$3.48 million-2.00Gap Up
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.68flat$5.50 million$9.47 million0.00Gap Up
AMBS
Amarantus BioScience
0.0$0.01flat$4.86 millionN/A0.00Increase in Short Interest
Gap Down
BCTXF
BriaCell Therapeutics
0.0$5.95flat$4.59 millionN/A-0.01News Coverage
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.11flat$4.49 million$3.65 million0.00Decrease in Short Interest
News Coverage
FutureWorld logo
FWDG
FutureWorld
0.5$0.00flat$3.80 millionN/A0.00
AKRXQ
Akorn
0.1$0.03flat$3.60 million$682.43 million-0.01
VGLS
VG Life Sciences
0.0$0.01flat$3.41 millionN/A0.00Increase in Short Interest
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02flat$3.00 million$20,000.00-1.01Gap Up
RSPI
RespireRx Pharmaceuticals
0.5$0.04flat$2.91 millionN/A-0.09
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
IMUCD
ImmunoCellular Therapeutics
0.0$0.50flat$2.10 millionN/A0.00Gap Up
NSPX
Inspyr Therapeutics
0.5$0.01flat$2.09 millionN/A0.00Gap Up
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.10flat$2.08 millionN/A0.00High Trading Volume
Increase in Short Interest
Gap Down
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$34.00flat$1.84 million$2 million0.00
WWHC
W World
0.8$6.09flat$1.80 millionN/A0.00Increase in Short Interest
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.51flat$1.80 millionN/A0.00Gap Down
Cardax logo
CDXI
Cardax
0.0$2.10flat$1.67 million$710,000.000.00
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03flat$1.54 million$530,000.000.00
MLNTQ
Melinta Therapeutics
0.2$0.11flat$1.51 million$96.43 million0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03flat$1.25 million$8.73 million0.00Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01flat$1.19 millionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05flat$1.12 millionN/A-0.57Upcoming Earnings
Decrease in Short Interest
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.05flat$1.12 millionN/A0.00Gap Up
ATRX
Adhera Therapeutics
0.0$0.08flat$1.11 million$250,000.000.00High Trading Volume
Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.23flat$1.05 millionN/A0.00Decrease in Short Interest
AOXG
Aoxing Pharmaceutical
0.5$0.01flat$1.05 millionN/A0.00
SPHS
Sophiris Bio
0.1$0.03flat$995,000.00N/A0.00Increase in Short Interest
Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07flat$970,000.00N/A0.00Increase in Short Interest
Gap Up
PXYN
Praxsyn
0.6$0.00flat$848,000.00N/A0.00Increase in Short Interest
STLT
Spotlight Innovation
0.5$0.02flat$772,000.00N/A0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03flat$771,000.00N/A0.00Gap Down
SKVI
Skinvisible
0.7$0.15flat$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05flat$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$9.08flat$454,000.00N/A0.00High Trading Volume
Gap Down
BSPM
Biostar Pharmaceuticals
0.0$0.17flat$449,000.00N/A0.00Gap Down
HSTC
HST Global
0.8$0.07flat$378,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47flat$338,000.00$36.55 million0.00Gap Up
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01flat$295,000.00N/A0.00High Trading Volume
Increase in Short Interest
News Coverage
WDBG
Woodbrook Group
0.0$1.60flat$207,000.00N/A0.00Gap Up
ROSGQ
Rosetta Genomics
0.0$0.07flat$124,000.00N/A0.00
MetaStat logo
MTST
MetaStat
0.0$0.02flat$118,000.00$20,000.000.00
PZRXQ
PhaseRx
0.2$0.03flat$108,000.00N/A0.00Decrease in Short Interest
Gap Down
OREXQ
Orexigen Therapeutics
0.4$0.01flat$100,000.00$33.71 million0.00Gap Up
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.